IL287057B2 - Purified iduronate-2-sulfatase - Google Patents

Purified iduronate-2-sulfatase

Info

Publication number
IL287057B2
IL287057B2 IL287057A IL28705721A IL287057B2 IL 287057 B2 IL287057 B2 IL 287057B2 IL 287057 A IL287057 A IL 287057A IL 28705721 A IL28705721 A IL 28705721A IL 287057 B2 IL287057 B2 IL 287057B2
Authority
IL
Israel
Prior art keywords
protein
recombinant
purified recombinant
seq
composition
Prior art date
Application number
IL287057A
Other languages
English (en)
Hebrew (he)
Other versions
IL287057A (en
IL287057B1 (en
Original Assignee
Shire Human Genetic Therapies
Takeda Pharmaceutical Co Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49778401&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL287057(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Human Genetic Therapies, Takeda Pharmaceutical Co Limited filed Critical Shire Human Genetic Therapies
Publication of IL287057A publication Critical patent/IL287057A/en
Publication of IL287057B1 publication Critical patent/IL287057B1/en
Publication of IL287057B2 publication Critical patent/IL287057B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL287057A 2012-06-29 2013-06-28 Purified iduronate-2-sulfatase IL287057B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666733P 2012-06-29 2012-06-29
PCT/US2013/048561 WO2014005014A2 (en) 2012-06-29 2013-06-28 Purification of iduronate-2-sulfatase

Publications (3)

Publication Number Publication Date
IL287057A IL287057A (en) 2021-12-01
IL287057B1 IL287057B1 (en) 2026-01-01
IL287057B2 true IL287057B2 (en) 2026-05-01

Family

ID=49778401

Family Applications (4)

Application Number Title Priority Date Filing Date
IL287057A IL287057B2 (en) 2012-06-29 2013-06-28 Purified iduronate-2-sulfatase
IL236315A IL236315A (en) 2012-06-29 2014-12-17 Compositions comprising purified recombinant iduronate-2-sulfatase
IL248727A IL248727A0 (en) 2012-06-29 2016-11-03 Purified iduronate-2-sulfatase
IL261264A IL261264B (en) 2012-06-29 2018-08-21 Purification of iduronate-2 sulfatase

Family Applications After (3)

Application Number Title Priority Date Filing Date
IL236315A IL236315A (en) 2012-06-29 2014-12-17 Compositions comprising purified recombinant iduronate-2-sulfatase
IL248727A IL248727A0 (en) 2012-06-29 2016-11-03 Purified iduronate-2-sulfatase
IL261264A IL261264B (en) 2012-06-29 2018-08-21 Purification of iduronate-2 sulfatase

Country Status (39)

Country Link
US (7) US9051556B2 (enExample)
EP (2) EP3441398A1 (enExample)
JP (4) JP6171007B2 (enExample)
KR (5) KR101380740B1 (enExample)
CN (3) CN107596358A (enExample)
AR (1) AR091647A1 (enExample)
AU (3) AU2013282395C1 (enExample)
BR (1) BR112014032567B1 (enExample)
CA (2) CA2877517C (enExample)
CL (1) CL2014003567A1 (enExample)
CO (1) CO7240396A2 (enExample)
CR (1) CR20140588A (enExample)
CY (1) CY1121519T1 (enExample)
DK (1) DK2867245T3 (enExample)
DO (1) DOP2014000294A (enExample)
EA (2) EA034549B1 (enExample)
ES (1) ES2689468T3 (enExample)
GT (1) GT201400303A (enExample)
HK (3) HK1209431A1 (enExample)
HR (1) HRP20181897T1 (enExample)
HU (1) HUE040769T2 (enExample)
IL (4) IL287057B2 (enExample)
LT (1) LT2867245T (enExample)
MX (3) MX366906B (enExample)
MY (3) MY180287A (enExample)
NZ (3) NZ703093A (enExample)
PE (1) PE20150720A1 (enExample)
PH (3) PH12014502871B1 (enExample)
PL (1) PL2867245T3 (enExample)
PT (1) PT2867245T (enExample)
RS (1) RS58005B1 (enExample)
SG (2) SG11201408761VA (enExample)
SI (1) SI2867245T1 (enExample)
SM (1) SMT201800612T1 (enExample)
TR (1) TR201815811T4 (enExample)
TW (2) TWI553120B (enExample)
UA (2) UA129561C2 (enExample)
WO (1) WO2014005014A2 (enExample)
ZA (2) ZA201409397B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3184105A1 (en) 2007-07-27 2009-02-05 Armagen Inc. Methods and compositions for increasing alpha-l-iduronidase activity in the cns
JP2013507131A (ja) 2009-10-09 2013-03-04 アーメイゲン・テクノロジーズ・インコーポレイテッド Ｃｎｓにおけるイズロン酸２−スルファターゼ活性を増加させるための方法および組成物
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US20160145589A1 (en) 2011-06-24 2016-05-26 Green Cross Corporation Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
CN109641971B (zh) 2016-08-25 2023-04-04 Jcr制药股份有限公司 抗体融合蛋白的制造方法
CN106282231B (zh) * 2016-09-06 2020-01-03 陕西慧康生物科技有限责任公司 粘多糖贮积症ii型动物模型的构建方法及应用
CN106428420B (zh) * 2016-10-17 2018-08-21 上海江南长兴造船有限责任公司 一种用于超大型集装箱船止裂钢舱口围的安装的方法
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
JP7458404B2 (ja) * 2018-12-20 2024-03-29 アーマジェン・インコーポレイテッド イズロン酸－２－スルファターゼ免疫グロブリン融合タンパク質の精製
MX2021008983A (es) * 2019-01-30 2021-09-08 Amgen Inc Atributos de aflibercept y metodos de caracterizacion y modificacion de los mismos.
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US12611447B2 (en) 2020-09-04 2026-04-28 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
AU2021364779B2 (en) * 2020-10-23 2026-08-13 Alexion Pharmaceuticals, Inc. Method of controlling total sialic acid content (tsac) during manufacturing of alkaline phosphatase
AU2022218782B2 (en) 2021-02-12 2026-06-25 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096555A (en) * 1995-07-26 2000-08-01 Dade Behring Marburg Gmbh Process for characterizing the glycosylation of glyco-proteins and for the in vitro determination of the bio-availability of glyco-proteins
US7323553B2 (en) * 2002-04-26 2008-01-29 Genentech, Inc. Non-affinity purification of proteins
US7541164B2 (en) * 2002-12-23 2009-06-02 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2011044542A1 (en) * 2009-10-09 2011-04-14 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns
US8128925B2 (en) * 2008-01-18 2012-03-06 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK6488D0 (da) 1988-01-07 1988-01-07 Novo Industri As Enzymer
US5310646A (en) 1988-05-13 1994-05-10 Regents Of The University Of Minnesota Method for the detection of mucopolysaccharide storage diseases
US5932211A (en) 1991-11-12 1999-08-03 Women's And Children's Hospital Glycosylation variants of iduronate 2-sulfatase
AU700369B2 (en) 1994-03-16 1999-01-07 Regents Of The University Of California, The Treating inflammation via the administration of specific sulfatase enzymes and/or sulfation inhibitor
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
EP2221361A3 (en) 1996-08-30 2011-02-09 Life Technologies Corporation Method for producing a polypeptide in vitro in mammalian cells in a protein-free and serum-free culture medium
US7368531B2 (en) 1997-03-07 2008-05-06 Human Genome Sciences, Inc. Human secreted proteins
AU3382800A (en) 1999-02-26 2000-09-14 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US7083793B2 (en) 1999-02-26 2006-08-01 Millennium Pharmaceuticals, Inc. Tango 243 polypeptides and uses thereof
CA2368797C (en) 1999-04-26 2010-08-17 Genentech, Inc. Cell culture process
JP2002017376A (ja) 1999-07-08 2002-01-22 Herikkusu Kenkyusho:Kk 分泌蛋白質、または膜蛋白質
EP1212343A4 (en) 1999-09-03 2004-11-03 Human Genome Sciences Inc 52 human secreted proteins
US6780627B1 (en) 2000-01-31 2004-08-24 Millennium Pharmaceuticals, Inc. 22438, 23553, 25278, and 26212 novel human sulfatases
AU2001238488A1 (en) 2000-02-17 2001-08-27 Incyte Genomics, Inc. Human kinases
WO2001070804A1 (en) 2000-03-17 2001-09-27 Human Genome Sciences, Inc. 7 human ovarian and ovarian cancer associated proteins
US6926898B2 (en) 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
US20030148920A1 (en) 2000-12-27 2003-08-07 Steven Rosen Sulfatases and methods of use thereof
WO2002098455A2 (en) 2001-06-07 2002-12-12 Hemebiotech A/S Production of recombinant human arylsulfatase a
US6890736B1 (en) 2002-09-20 2005-05-10 Immunex Corporation Methods for producing proteins in cultured cells
JP4606712B2 (ja) * 2003-01-08 2011-01-05 マサチューセッツ インスティテュート オブ テクノロジー ２−ｏスルファターゼ組成物および関連の方法
CN110496230A (zh) 2003-02-11 2019-11-26 夏尔人类遗传性治疗公司 使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
US20050019914A1 (en) 2003-07-24 2005-01-27 Aventis Pharma Deutschland Gmbh Perfusion process for producing erythropoietin
NZ576986A (en) 2004-01-30 2010-12-24 Shire Pharmaceuticals Ireland Ltd Production and purification of recombinant arylsulfatase A
WO2005113765A2 (en) 2004-05-06 2005-12-01 Biomarin Pharmaceutical Inc. Methods of activation of sulfatases and methods and compositions of using the same
CA2609060C (en) 2005-06-03 2014-07-15 Urs Weber Production of recombinant il-18 binding protein
US20100190210A1 (en) 2006-03-20 2010-07-29 Medarex, Inc. Protein Purification
JP4458377B2 (ja) 2007-06-29 2010-04-28 キヤノン株式会社 プロセスカートリッジ及び電子写真画像形成装置
US20130195888A1 (en) 2007-11-30 2013-08-01 Abbvie Ultrafiltration and diafiltration formulation methods for protein processing
WO2011108451A1 (ja) * 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
KR20130043165A (ko) 2010-06-25 2013-04-29 샤이어 휴먼 지네틱 테라피즈 인크. 이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
CN103269709A (zh) * 2010-06-25 2013-08-28 夏尔人类遗传性治疗公司 Sanfilippo综合症类型B的治疗
AR082319A1 (es) 2010-07-22 2012-11-28 Biomarin Pharm Inc Produccion de una n-acetilgalactosamina-6-sulfatasa humana activa altamente fosforilada y sus usos
JP5865839B2 (ja) * 2010-09-28 2016-02-17 共立製薬株式会社 粘膜アジュバント組成物
WO2012101671A1 (en) 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
WO2012105954A1 (en) 2011-01-31 2012-08-09 Hewlett-Packard Development Company, L. P. A diffuser with a dynamically tunable scattering angle
KR101158673B1 (ko) 2011-06-24 2012-07-03 주식회사 지씨바이오 재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
US9150841B2 (en) 2012-06-29 2015-10-06 Shire Human Genetic Therapies, Inc. Cells for producing recombinant iduronate-2-sulfatase
US20140004097A1 (en) 2012-06-29 2014-01-02 Shire Human Genetic Therapies, Inc. Method of producing recombinant iduronate-2-sulfatase
KR101380740B1 (ko) 2012-06-29 2014-04-11 쉐어 휴먼 제네텍 세러피스, 인코포레이티드 이듀로네이트-2-설파타제의 정제
KR20190062745A (ko) 2017-11-29 2019-06-07 주식회사 위니플 쇼핑몰 모바일앱 빌더

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096555A (en) * 1995-07-26 2000-08-01 Dade Behring Marburg Gmbh Process for characterizing the glycosylation of glyco-proteins and for the in vitro determination of the bio-availability of glyco-proteins
US7323553B2 (en) * 2002-04-26 2008-01-29 Genentech, Inc. Non-affinity purification of proteins
US7541164B2 (en) * 2002-12-23 2009-06-02 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
US8128925B2 (en) * 2008-01-18 2012-03-06 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
WO2011044542A1 (en) * 2009-10-09 2011-04-14 Armagen Technologies, Inc. Methods and compositions for increasing iduronate 2-sulfatase activity in the cns

Also Published As

Publication number Publication date
PL2867245T3 (pl) 2019-02-28
US9492511B2 (en) 2016-11-15
AU2018200230B2 (en) 2020-01-02
WO2014005014A3 (en) 2014-02-27
KR20140004603A (ko) 2014-01-13
IL236315A0 (en) 2015-02-26
US20170073652A1 (en) 2017-03-16
BR112014032567A2 (pt) 2017-08-01
US20150313972A1 (en) 2015-11-05
UA121959C2 (uk) 2020-08-25
KR101380740B1 (ko) 2014-04-11
IL261264B (en) 2021-10-31
IL261264A (en) 2018-10-31
KR20220002227A (ko) 2022-01-06
CY1121519T1 (el) 2020-05-29
MX393364B (es) 2025-03-19
HK1209431A1 (en) 2016-04-01
WO2014005014A2 (en) 2014-01-03
IL248727A0 (en) 2017-01-31
PH12020500027A1 (en) 2021-03-15
JP6171007B2 (ja) 2017-07-26
US12359178B2 (en) 2025-07-15
US20240401010A1 (en) 2024-12-05
CA2877517C (en) 2018-07-31
EA034549B1 (ru) 2020-02-19
DOP2014000294A (es) 2015-03-15
MX366906B (es) 2019-07-30
AU2013282395C1 (en) 2016-03-24
SG10201703489VA (en) 2017-05-30
PT2867245T (pt) 2018-11-26
AU2013282395A1 (en) 2015-01-29
PH12014502871A1 (en) 2015-02-23
SG11201408761VA (en) 2015-01-29
NZ703093A (en) 2017-08-25
MX336715B (es) 2016-01-28
MY157087A (en) 2016-04-19
PH12014502871B1 (en) 2015-02-23
CN107596358A (zh) 2018-01-19
JP6505629B2 (ja) 2019-04-24
US20210317426A1 (en) 2021-10-14
BR112014032567B1 (pt) 2022-09-13
EP3441398A1 (en) 2019-02-13
AU2016200469B2 (en) 2017-10-12
IL287057A (en) 2021-12-01
JP2016119911A (ja) 2016-07-07
EA202090044A1 (ru) 2020-07-31
NZ733366A (en) 2019-12-20
CA2877517A1 (en) 2014-01-03
NZ743910A (en) 2019-12-20
GT201400303A (es) 2017-08-31
CN104583225A (zh) 2015-04-29
CN107596357A (zh) 2018-01-19
RS58005B1 (sr) 2019-02-28
CA3008945A1 (en) 2014-01-03
CO7240396A2 (es) 2015-04-17
US20190359958A1 (en) 2019-11-28
TR201815811T4 (tr) 2018-11-21
IL287057B1 (en) 2026-01-01
US9051556B2 (en) 2015-06-09
JP7594365B2 (ja) 2024-12-04
PE20150720A1 (es) 2015-05-16
UA129561C2 (uk) 2025-06-04
DK2867245T3 (en) 2018-11-26
AR091647A1 (es) 2015-02-18
TWI553120B (zh) 2016-10-11
EA201492177A1 (ru) 2015-06-30
HRP20181897T1 (hr) 2019-01-11
KR20190064542A (ko) 2019-06-10
AU2013282395B2 (en) 2015-12-03
TW201410868A (zh) 2014-03-16
CR20140588A (es) 2015-04-06
HK1209767A1 (en) 2016-04-08
HK1249027A1 (zh) 2018-10-26
MX2019008914A (es) 2019-09-26
PH12015502408B1 (en) 2020-02-14
IL236315A (en) 2016-11-30
SI2867245T1 (sl) 2018-12-31
JP2015523072A (ja) 2015-08-13
KR20140002451A (ko) 2014-01-08
US10344270B2 (en) 2019-07-09
LT2867245T (lt) 2018-11-12
EP2867245A2 (en) 2015-05-06
US20140004096A1 (en) 2014-01-02
MY180287A (en) 2020-11-27
US11530393B2 (en) 2022-12-20
KR20200143339A (ko) 2020-12-23
JP2018121645A (ja) 2018-08-09
SMT201800612T1 (it) 2019-01-11
ZA201803289B (en) 2021-04-28
MX2015000190A (es) 2015-04-08
TWI587869B (zh) 2017-06-21
EP2867245A4 (en) 2016-03-09
ES2689468T3 (es) 2018-11-14
ZA201409397B (en) 2019-10-30
HK1249026A1 (zh) 2018-10-26
AU2016200469A1 (en) 2016-02-18
JP2020105209A (ja) 2020-07-09
AU2018200230A1 (en) 2018-02-01
EP2867245B1 (en) 2018-09-12
MY192068A (en) 2022-07-25
PH12015502408A1 (en) 2018-03-26
TW201703794A (zh) 2017-02-01
HUE040769T2 (hu) 2019-03-28
CL2014003567A1 (es) 2015-04-24
US20240043817A1 (en) 2024-02-08

Similar Documents

Publication Publication Date Title
IL248727A0 (en) Purified iduronate-2-sulfatase
ZA201501847B (en) Formulations of enzalutamide
ZA201406082B (en) Use of ccr3-inhibitors
SG11201403891SA (en) Purification of flaviviruses
GB201513279D0 (en) Micro-evolution of microbes
IL263162B (en) Purification of cystathionine beta-synthase
SG11201406800UA (en) Purification of air
GB201501016D0 (en) Preparation of 18F-fluciclovine
PL2888228T3 (pl) Inhibitory oddziaływania CD40-TRAF6
GB201207907D0 (en) Treatment of depression
TWM433525U (en) Structure of calorifier
GB201212279D0 (en) Method of construction
GB201217666D0 (en) Construction of surfaces
GB201218263D0 (en) Treatment of autism
IL233740A0 (en) Treatment of liver diseases
GB201204173D0 (en) Water purification
GB201221118D0 (en) Methods of treatment
GB201216740D0 (en) Methods of treatment
GB201216748D0 (en) Methods of treatment
GB201206330D0 (en) Methods of treatment
GB201206326D0 (en) Methods of treatment
GB201206324D0 (en) Methods of treatment
GB201206325D0 (en) Methods of treatment
GB201121044D0 (en) Treatment of solutions